[{"address1": "1065 East Hillsdale Boulevard", "address2": "Suite 100", "city": "Foster City", "state": "CA", "zip": "94404", "country": "United States", "phone": "650 525 5535", "fax": "650 275 4254", "website": "https://www.ternspharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.", "fullTimeEmployees": 66, "companyOfficers": [{"maxAge": 1, "name": "Ms. Amy L. Burroughs M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elona  Kogan Esq., J.D.", "age": 55, "title": "Chief Legal Officer", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey R. Jasper Ph.D.", "title": "Senior Vice President of Research", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Emil T. Kuriakose M.D.", "age": 44, "title": "Chief Medical Officer", "yearBorn": 1980, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melita Sun Jung", "age": 47, "title": "Chief Business Officer", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Harris", "title": "Chief Development Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Debra  Sieminski", "title": "Senior Vice President of Medical Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Kanter", "title": "Senior VP of CMC", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Eric Strauss", "age": 38, "title": "VP of Finance & Controller", "yearBorn": 1986, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "maxAge": 86400, "priceHint": 4, "previousClose": 4.08, "open": 4.09, "dayLow": 4.03, "dayHigh": 4.19, "regularMarketPreviousClose": 4.08, "regularMarketOpen": 4.09, "regularMarketDayLow": 4.03, "regularMarketDayHigh": 4.19, "beta": -0.357, "forwardPE": -3.0830214, "volume": 1043711, "regularMarketVolume": 1043711, "averageVolume": 1849827, "averageVolume10days": 1582520, "averageDailyVolume10Day": 1582520, "bid": 2.97, "ask": 5.22, "bidSize": 200, "askSize": 200, "marketCap": 344851904, "fiftyTwoWeekLow": 4.03, "fiftyTwoWeekHigh": 11.4, "fiftyDayAverage": 5.3669, "twoHundredDayAverage": 6.8669, "currency": "USD", "enterpriseValue": -26620248, "floatShares": 56094469, "sharesOutstanding": 84938896, "sharesShort": 6454514, "sharesShortPriorMonth": 7369540, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.076, "heldPercentInsiders": 0.00259, "heldPercentInstitutions": 1.05607, "shortRatio": 3.4, "shortPercentOfFloat": 0.083500005, "impliedSharesOutstanding": 84938896, "bookValue": 4.292, "priceToBook": 0.945946, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -88073000, "trailingEps": -1.18, "forwardEps": -1.39, "enterpriseToEbitda": 0.267, "52WeekChange": -0.45381528, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TERN", "underlyingSymbol": "TERN", "shortName": "Terns Pharmaceuticals, Inc.", "longName": "Terns Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7e7e889b-1f93-38a3-8cbf-64bb942bfd16", "messageBoardId": "finmb_558294166", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.06, "targetHighPrice": 34.0, "targetLowPrice": 7.5, "targetMeanPrice": 19.0625, "targetMedianPrice": 19.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 372776992, "totalCashPerShare": 4.389, "ebitda": -99655000, "totalDebt": 1305000, "quickRatio": 32.665, "currentRatio": 32.992, "debtToEquity": 0.358, "returnOnAssets": -0.19229001, "returnOnEquity": -0.28279, "freeCashflow": -45897500, "operatingCashflow": -74748000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]